At a glance
ClinicalIndex Comparison RecordPhase 2Active· 29 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Ruxolitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Oct 29, 2018·Updated Apr 2, 2026
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib for Chronic Myelomonocytic Leukemia and Leukemia. Active but no longer recruiting, targeting 29 participants across 5 sites.
Detailed Summary
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myelomonocytic Leukemia, Leukemia
CountriesUnited States
CollaboratorsIncyte Corporation
Timeline
Phase 2ActiveOverdue
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartAug 2019
Primary CompletionSep 2022
Study CompletionJun 2026
TodayJul 2026
First PostedOct 29, 2018
Enrollment StartAug 28, 2019
Primary CompletionSep 19, 2022
Study CompletionJun 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.7 years ago
Interventions
Ruxolitinibdrug
Ruxolitinib 5 mg tablets, 4 per dose